Befovacimab (Anti-TFPI)

Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in  haemophilia A/B research. MW: 143.24 kD.

• Supplier: Selleck Chemicals
• Product #: A2779
• Sku #: A2779-1mg